CFO James Andrea S. bought 97,561 shares of OCX at $2.05 (+181.8% to holdings); stock at $2.37, down 29.5% from 52-week high.
CFO James Andrea S. purchased 97,561 shares at $2.05 on 2025-02-07, increasing his holdings from 53,670 to 151,231 shares. The transaction occurred while the stock trades at $2.37, approximately 29.5% below its 52-week high of $3.36, following a 90-day decline of 19.4%. His prior trade at OCX on 2024-10-02 resulted in a 90-day loss of 19.9%, and his cross-ticker track record shows a 0.00% win rate at the 90-day mark across 2 prior buys. The company reported revenue of $115,000.00 in its latest quarter with net losses of $13.5M and was unprofitable over its most recent full fiscal year, despite annual revenue growth of 56.9%. A cluster pattern shows 2 other insiders also bought within the past 14 days, suggesting broader executive interest at current valuations.
CFO James Andrea buys 20,000 OCX shares at $2.29; stock down -22.3% in 90 days; company unprofitable with $-13.5M net loss.
CFO James Andrea purchased 20,000 shares at $2.29 on 2024-12-05, increasing his holdings by 59.4% to 53.7K shares—a substantial position increase. The transaction occurs in a context of material headwinds: the stock is down -22.3% over 90 days and down -35.9% from its 52-week high of $3.84, trading at $2.46 currently. Oncocyte remains unprofitable with a $-13.5M net loss in its most recent fiscal year, though the company showed strong +56.9% annual revenue growth. His prior open-market buy at OCX in October also showed modest 30-day gains (+1.0%), but the subsequent 90-day window remains unmeasurable, leaving no historical pattern of well-timed entries at this ticker. The magnitude of the position increase during a sharp equity decline warrants attention to whether this reflects conviction in recovery or is a required/scheduled action, but the transaction alone does not resolve that distinction.
CFO James Andrea buys $100.0K of OCX at $2.97; stock down 32.2% from 52-week high despite +56.9% annual revenue growth.
CFO James Andrea purchased 33,670 shares for $99,999.90 at $2.97, establishing his first measured position in Oncocyte. The transaction occurs while the stock trades at $2.89—32.2% below its 52-week high of $4.26—despite annual revenue growth of +56.9%, suggesting a valuation disconnect. The company posted a net loss of $-4.5M in its most recent full fiscal year and revenues of $104.0K in the latest quarter, indicating severe profitability challenges. The insider's purchase at depressed price levels coincides with fundamental weakness and should be monitored for materiality, but the modest position size relative to the company's $38.6M market cap and absence of prior trading context limit the certainty of its signal.
